Cobalt-Doped Iron Phosphate Crystal on Stainless Steel Mesh for Corrosion-Resistant Oxygen Evolution Catalyst

We report an oxygen evolution reaction (OER) catalyst prepared by the incorporation of cobalt-doped iron phosphate on stainless steel mesh (SSM) through a one-step hydrothermal method. Compared to the catalytic property of bare SSM, our OER catalyst (0.84-CoFePi) showed a 42% improvement in current density at the potential of 1.9 V vs. RHE, and the onset potential was decreased by 26.5 mV. Furthermore, the loss in current density of bulk electrolysis after 12 h in 1 M KOH (pH 14) solution and 0.0441 wt% H2SO4 (pH ≈ 3) containing 0.1 M NaCl solution was negligible (3.1% and 3.2%, respectively). Moreover, our cobalt-doped iron phosphate on SSM exhibits the dramatic improvement in corrosion resistance to a basic, mild acidic solution and chloride ions compared to bare SSM

Cobalt-Doped Iron Phosphate Crystal on Stainless Steel Mesh for Corrosion-Resistant Oxygen Evolution Catalyst

We report an oxygen evolution reaction (OER) catalyst prepared by the incorporation of cobalt-doped iron phosphate on stainless steel mesh (SSM) through a one-step hydrothermal method. Compared to the catalytic property of bare SSM, our OER catalyst (0.84-CoFePi) showed a 42% improvement in current density at the potential of 1.9 V vs. RHE, and the onset potential was decreased by 26.5 mV. Furthermore, the loss in current density of bulk electrolysis after 12 h in 1 M KOH (pH 14) solution and 0.0441 wt% H2SO4 (pH ≈ 3) containing 0.1 M NaCl solution was negligible (3.1% and 3.2%, respectively). Moreover, our cobalt-doped iron phosphate on SSM exhibits the dramatic improvement in corrosion resistance to a basic, mild acidic solution and chloride ions compared to bare SSM

Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach

Major depressive disorder (MDD) is a common disorder involving depressive mood and decreased motivation. Due to its high heterogeneity, novel biomarkers are required to diagnose MDD. In this study, a proteomic method was used to identify a new MDD biomarker. Using sequential window acquisition of all theoretical mass spectra acquisitions and multiple reaction monitoring analysis via mass spectrometry, relative and absolute quantification of proteins in the sera was performed. The results of the relative quantitation by sequential window acquisition for all theoretical mass spectra data showed that seven proteins were significantly differently expressed between MDD patients and other patients with remission status. However, absolute quantification by multiple reaction monitoring analysis identified prothrombin as the only significantly upregulated protein in the depressive state compared to remission (p < 0.05) and was, thus, subsequently selected as an MDD biomarker. The area under the curve for prothrombin was 0.66. Additionally, increased prothrombin/thrombin induced hyper-activation of platelets via activating protease-activated receptors, a feature associated with MDD; specifically, activated platelets secrete various molecules related to MDD, including brain-derived neurotropic factors and serotonin. Therefore, prothrombin is a potential screening, prognostic, and diagnostic marker for MDD

Adsorption of Glucose Molecules on Stainless Steel Enables Ni‐Rich Passivation Film

Abstract Stainless steel (SS) is well known for its remarkable versatility. Besides the importance of passivation film for durability and stability of SS, the composition and morphology of passive surface layer have to be precisely modified to create an alloy that is optimal for specific purposes. Herein, we report on the electrochemical preparation of nickel‐enriched passive film which is accomplished by the preferential adsorption of glucose on nickel species among constituents of SS. The presence of nickel‐rich surface and the exposure of nickel on the outmost surface layer participating in surface reactions are verified by monitoring redox couple of Ni2+/Ni3+ as well as elemental analyses (TEM‐Energy‐dispersive X‐ray spectroscopy, X‐ray photoelectron spectroscopy). Reversible interchange of nickel‐rich into iron‐rich surface and vice versa is possible by adding or removing glucose. We find that molecules having more than tri‐dentate of hydroxy groups (e. g. glycerol) is required for the formation of Ni‐rich surface (chelate effect)

Reduced Graphene Oxide Supported Cobalt-Calcium Phosphate Composite for Electrochemical Water Oxidation

We report the oxygen evolution reaction (OER) catalyst composed of cobalt–calcium phosphate on reduced graphene oxide (CoCaP/rGO). Our catalyst is prepared by the anodic electrolysis of calcium phosphate/rGO mixture loaded on indium-tin-oxide (ITO) in Co2+ aqueous solution. TEM, XPS and XRD experiments confirm that the crystal phase of calcium phosphate (CaP) is transferred into an amorphous phase of calcium oxide with phosphate (5.06 at%) after anodic electrolysis. Additionally, the main cation component of calcium is replaced by cobalt ion. The current–voltage characteristics of CoCaP/rGO showed a shoulder peak at 1.10 V vs. NHE, which originated from Co2+ to higher oxidation states (Co3+ or Co4+) and a strong wave from water oxidation higher +1.16 V vs. NHE at neutral condition (pH 7). CoCaP and CoCaP/rGO showed 4.8 and 10 mA/cm2 at 0.47 V of overpotential, respectively. The enhanced OER catalytic activity of CoCaP/rGO arises from the synergetic interaction between the amorphous phase of CoCaP and electric conducting graphene sheets

Dual Oxidase 2 (DUOX2) as a Proteomic Biomarker for Predicting Treatment Response to Chemoradiation Therapy for Locally Advanced Rectal Cancer: Using High-Throughput Proteomic Analysis and Machine Learning Algorithm

High-throughput mass-spectrometry-based quantitative proteomic analysis was performed using formalin-fixed, paraffin-embedded (FFPE) biopsy samples obtained before treatment from 13 patients with locally advanced rectal cancer (LARC), who were treated with concurrent chemoradiation therapy (CCRT) followed by surgery. Patients were divided into complete responder (CR) and non-complete responder (nCR) groups. Immunohistochemical (IHC) staining of 79 independent FFPE tissue samples was performed to validate the predictive ability of proteomic biomarker candidates. A total of 3637 proteins were identified, and the expression of 498 proteins was confirmed at significantly different levels (differentially expressed proteins—DEPs) between two groups. In Gene Ontology enrichment analyses, DEPs enriched in biological processes in the CR group included proteins linked to cytoskeletal organization, immune response processes, and vesicle-associated protein transport processes, whereas DEPs in the nCR group were associated with biosynthesis, transcription, and translation processes. Dual oxidase 2 (DUOX2) was selected as the most predictive biomarker in machine learning algorithm analysis. Further IHC validation ultimately confirmed DUOX2 as a potential biomarker for predicting the response of nCR to CCRT. In conclusion, this study suggests that the treatment response to RT may be affected by the pre-treatment tumor microenvironment. DUOX2 is a potential biomarker for the early prediction of nCR after CCRT

Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer

Background Chemotherapy is the standard treatment for breast cancer; however, the response to chemotherapy is disappointingly low. Here, we investigated the alternative therapeutic efficacy of novel combination treatment with necroptosis-inducing small molecules to overcome chemotherapeutic resistance in tyrosine aminoacyl-tRNA synthetase (YARS)-positive breast cancer. Methods Pre-chemotherapeutic needle biopsy of 143 invasive ductal carcinomas undergoing the same chemotherapeutic regimen was subjected to proteomic analysis. Four different machine learning algorithms were employed to determine signature protein combinations. Immunoreactive markers were selected using three common candidate proteins from the machine-learning algorithms and verified by immunohistochemistry using 123 cases of independent needle biopsy FFPE samples. The regulation of chemotherapeutic response and necroptotic cell death was assessed using lentiviral YARS overexpression and depletion 3D spheroid formation assay, viability assays, LDH release assay, flow cytometry analysis, and transmission electron microscopy. The ROS-induced metabolic dysregulation and phosphorylation of necrosome complex by YARS were assessed using oxygen consumption rate analysis, flow cytometry analysis, and 3D cell viability assay. The therapeutic roles of SMAC mimetics (LCL161) and a pan-BCL2 inhibitor (ABT-263) were determined by 3D cell viability assay and flow cytometry analysis. Additional biologic process and protein-protein interaction pathway analysis were performed using Gene Ontology annotation and Cytoscape databases. Results YARS was selected as a potential biomarker by proteomics-based machine-learning algorithms and was exclusively associated with good response to chemotherapy by subsequent immunohistochemical validation. In 3D spheroid models of breast cancer cell lines, YARS overexpression significantly improved chemotherapy response via phosphorylation of the necrosome complex. YARS-induced necroptosis sequentially mediated mitochondrial dysfunction through the overproduction of ROS in breast cancer cell lines. Combination treatment with necroptosis-inducing small molecules, including a SMAC mimetic (LCL161) and a pan-BCL2 inhibitor (ABT-263), showed therapeutic efficacy in YARS-overexpressing breast cancer cells. Conclusions Our results indicate that, before chemotherapy, an initial screening of YARS protein expression should be performed, and YARS-positive breast cancer patients might consider the combined treatment with LCL161 and ABT-263; this could be a novel stepwise clinical approach to apply new targeted therapy in breast cancer patients in the future